top of page
News, Events and Updates
Search
Nov 20, 2013
Anavex Announces Expansion of Scientific Advisory Board
Nov 18, 2013
Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of AD
Nov 12, 2013
Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer's Disease
Nov 11, 2013
Blockade of Tau Hyperphosphorylation and Ab1-42 Generation by the Aminotetrahydrofuran Derivative...
Nov 11, 2013
Chronic Treatment with the Tetrahydrofuran Derivative ANAVEX 2-73, a Mixed Muscarinic Cholinergic...
Nov 7, 2013
Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
Nov 4, 2013
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of AD
Oct 28, 2013
Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting
Oct 21, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
Sep 22, 2013
Anavex Comments on Newly Released World Alzheimer Report 2013
Sep 2, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
39
40
41
42
43
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
